Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Research Report 1 - Business Express

Biopharmaceutical Contract Manufacturing Market Value of US$ 18.7 Billion by 2029, at a CAGR of 10.5% from 2022 to 2029

Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.

Global Biopharmaceutical Contract Manufacturing Market was estimated to be worth roughly US$ 8.4 billion in 2021 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.

Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies. On the back of these factors, several large companies have outsourced their biopharmaceutical manufacturing operations. Biopharmaceutical contract manufacturing is highly preferred among biopharmaceutical companies with limited in-house production capacity.

Pharmaceutical companies mainly focus on core areas of competence, and hence, do not prefer to take financial risks in the event of formulating the final dose of medicines. This is anticipated to accelerate the growth of the global biopharmaceutical contract manufacturing market during forecast period, estimated to be valued at US$ 18.7 Bn by 2029.

Get a Sample PDF Report:

Regional Insights:

The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period.

Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.

China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth.

Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”

Ask An Analyst@ 

Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study

  • Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
  • In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
  • North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players.
  • The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.

Key Market Players:

  • Catalent Inc.
  • Lonza Group Ag
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Abzena Plc.
  • Sandoz International GmbH (Novartis AG)
  • Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
  • Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
  • AbbVie Contract Manufacturing (AbbVie Inc.)
  • Samsung Biologics Co. Ltd.
  • ProBioGen AG
  • Pfizer Centre Source Ltd (Pfizer Inc.)
  • Novasep
  • Biomeva GmbH
  • Kbi Biopharma Inc
  • Rentschler Biotechnologie GmbH
  • Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)

Request Customization@ 

Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research:

By Platform Type:

  • Mammalian Based
  • Microbial Based

By Product Type:

  • Monoclonal Antibodies
  • Recombinant Protein
  • Vaccine
  • Insulin
  • Growth factor
  • Interferons
  • Others

By Application Type:

  • Clinical
  • Commercial

By Therapeutic Area Type:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Diseases
  • Ophthalmology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurology
  • Respiratory Disorders
  • Others

Get Full Access: 

Table of Content

  1. Executive Summary


    1.1. Market Overview


    1.2. Market Analysis

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


    1.3. Analysis and Recommendations


  1. Market Introduction


    2.1. Market Coverage / Taxonomy


    2.2. Market Definition / Scope / Limitations


  1. Market Background


    3.1. Macro-Economic Factors


    3.2. Opportunity Analysis


    3.3. Regulatory Overview


Request a Complete TOC of this Report@ 

Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain

Dementia Management Market Size: The global dementia management market is anticipated to reach a market value of US$ 35 million in 2023 and to reach a market value of US$ 75.56 million by achieving an 8% CAGR from 2023 to 2033. 

Cryoglobulinemia Treatment Market Share: The global cryoglobulinemia treatment market is anticipated to reach a market value of US$ 496 Million in 2023 and US$ 888.26 Million by 2033, showing a CAGR of 6% during that time. 

Healthcare Cloud Infrastructure Market Trends: According to a recently published Future Market Insights analysis report, the global market for healthcare cloud infrastructure is expected to generate sales of $45.1 billion by 2022. By 2033, the market is anticipated to have grown at a CAGR of 23.9% and be worth US$464.1 billion. 

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

LinkedInTwitterBlogs | YouTube

For Sales Enquiries:


Recent Post: